Department of Medicine, Cardeza Foundation for Hematologic Research, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Laboratoire LIBM EA7424, Equipe "Biologie Vasculaire et du Globule Rouge", Université Claude Bernard Lyon 1, Villeurbanne, France.
Eur J Haematol. 2018 Dec;101(6):798-803. doi: 10.1111/ejh.13173. Epub 2018 Oct 9.
Determine the effect of fetal hemoglobin (HbF) and α-thalassemia on red blood cell (RBC) deformability of patients with sickle-cell anemia (SCA) with and without hydroxyurea (HU).
Adult patients were enrolled in the Sickle Cell Program of the Cardeza Foundation (Thomas Jefferson University) and were followed up prospectively during the period in which the Multicenter Study of Hydroxyurea (MSH) in patients with SCA was conducted. Ninety-one patients did not receive HU, 20 patients were enrolled in MSH, and 10 patients were enrolled in an open-label study of HU in SCA. Of the 20 patients enrolled in MSH, 11 took HU and nine took placebo. Control group included 113 normal individuals. Red blood cell deformability index (DI) was measured by ektacytometry.
Patients with SCA taking HU (n = 21) had higher DI than those taking placebo (n = 9) or who were not taking this therapy (n = 91). In patients without therapy, those with α-thalassemia (n = 31) had higher DI than those without. We showed a significant positive correlation between the level of HbF and DI. SCA patients without α-thalassemia and HbF <10% (n = 48) had lower DI than patients with α-thalassemia and HbF <10% (n = 23) and patients with (n = 8) or without α-thalassemia but with HbF >10% (n = 12). DI measured in patients without α-thalassemia and HbF >10% was higher than in the three other subgroups.
Elevated levels of HbF with or without HU and α-thalassemia improve sickle RBC rheology, which, in turn, improve the clinical picture of SCA.
确定胎儿血红蛋白 (HbF) 和α-地中海贫血对接受和未接受羟基脲 (HU) 治疗的镰状细胞贫血 (SCA) 患者红细胞 (RBC) 变形能力的影响。
成年患者参加了 Cardeza 基金会 (托马斯杰斐逊大学) 的镰状细胞计划,并在多中心 HU 在 SCA 患者中的研究进行期间进行前瞻性随访。91 例患者未接受 HU 治疗,20 例患者参加 MSH,10 例患者参加 SCA 中 HU 的开放标签研究。在参加 MSH 的 20 例患者中,11 例服用 HU,9 例服用安慰剂。对照组包括 113 名正常个体。通过 ektacytometry 测量红细胞变形指数 (DI)。
服用 HU 的 SCA 患者(n=21)的 DI 高于服用安慰剂的患者(n=9)或未接受该治疗的患者(n=91)。未接受治疗的患者中,有α-地中海贫血的患者(n=31)的 DI 高于无α-地中海贫血的患者。我们显示 HbF 水平与 DI 呈显著正相关。无α-地中海贫血且 HbF<10%的 SCA 患者(n=48)的 DI 低于有α-地中海贫血且 HbF<10%的患者(n=23)和有(n=8)或无α-地中海贫血但 HbF>10%的患者(n=12)。无α-地中海贫血且 HbF>10%的患者的 DI 高于其他三个亚组。
无论是否存在 HU 和α-地中海贫血,HbF 水平升高均可改善镰状红细胞流变学,从而改善 SCA 的临床症状。